Opsona Therapeutics Ltd

DUBLIN - Completed Series B Total Stands at EUR21.3 m DUBLIN, May 19 /PRNewswire/ -- Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced that Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3 million to the Series B financing announced in February this year, bringing the total round to EUR21.3 million.